key: cord-0921568-y0hzwsaj
authors: Uno, Yoshiharu
title: Why does SARS-CoV-2 invade the gastrointestinal epithelium?
date: 2020-04-10
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.04.006
sha: 4f32fd55da030ce155595633829b55b5299b67d9
doc_id: 921568
cord_uid: y0hzwsaj

nan

There are two key findings in this study. The first is the surprising fact that coronaviruses are present in the highly acidic gastric epithelium-the spike virus titer, regardless of the temperature (from 4 to 37 °C) [2] . In other words, in order for the SARS-CoV-2 virus to invade epithelial cells without being inactivated in the stomach, the gastric pH must be neutral.

The second important finding is that patients who tested positive on In the stomachs of patients with IM and/or AG, the pH of the surface of the gastric mucosa rises to 3 or more [4] , and for elderly AG, the pH found is 5-7 [5] .

Based on the above data, in the stomachs of elderly people with advanced chronic gastritis, it is presumed that the SARS-CoV-2 virus is not inactivated by 4 4 4 / 5 5 5 5 stomach acid, but instead enters the epithelial cells of the stomach, and further invades the epithelial cells of the small and large intestines.

If this hypothesis is correct, an individual with a history of HP infection may be susceptible to fecal-oral infection. In the report from China, blood group A had a significantly higher risk for COVID-19 compared with non-A blood groups, whereas blood group O had a significantly lower risk for the infectious disease compared with non-O blood groups [6] . According to more than 2,000 case-control studies in Japan, blood group A is susceptible to HP infection and AG [7] . Similarly, in Chinese case-control studies, the proportion of HP infection in blood-group A individuals was significantly higher than that of non-A blood groups [8] . These facts indicate that for individuals with blood group A, the route of viral transmission is likely to include the risk of gastrointestinal infections, in addition to those of the respiratory tract. There are also concerns that users of drugs such as proton pump inhibitors or potassium-competitive acid blockers for treating gastroesophageal reflux disease-regardless of whether they have blood type A, chronic gastritis, or HP infection-may be similarly at risk.

Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology